Mounjaro’s Launch in India Sparks Weight-Loss Drug Demand Surge

April 15, 2025 — The introduction of Eli Lilly’s weight-loss and diabetes medication, Mounjaro (tirzepatide), into the Indian market has led to a significant increase in patient inquiries and interest. Priced between ₹14,000 and ₹17,500 per month, depending on dosage, Mounjaro offers a more affordable and regulated alternative to black-market sources, where patients previously paid over ₹80,000 monthly for imported versions.

Medical institutions, such as Manipal Hospitals, have reported a 20% rise in weight-loss treatment inquiries since Mounjaro’s launch. This surge underscores the growing demand for effective obesity treatments in India, a country grappling with rising obesity and type 2 diabetes rates.

Intensified Market Competition

Mounjaro’s entry has intensified competition in the Indian pharmaceutical landscape. Key developments include:

• Novo Nordisk is expediting the launch of its obesity drug, Wegovy, in India, aiming for a 2026 release, ahead of its initial schedule.
• Indian pharmaceutical companies like Sun Pharmaceutical, Dr. Reddy’s Laboratories, and Cipla are actively developing generic versions of GLP-1-based therapies to capture a share of the burgeoning market.

Clinical Efficacy and Public Health Impact

Clinical trials have demonstrated Mounjaro’s effectiveness, with patients experiencing an average weight loss of 15.4 kg to 21.8 kg over 72 weeks, depending on dosage. The drug functions by activating both GIP and GLP-1 hormone receptors, aiding in blood sugar regulation and appetite suppression.

India’s escalating obesity and diabetes prevalence highlights the importance of accessible treatments. The launch of Mounjaro represents a significant step toward addressing these public health challenges.